Test Your Biomarkers’ Post

MYTH All stomach cancers are the same, and every patient has the same treatment plan. FACT Stomach cancers are NOT all the same, and each patient’s type of stomach cancer has a unique set of biomarkers. – Biomarkers are bits of information unique to you and your cancer. Cancer cell biomarkers can be genes, gene mutations, or proteins that cause cancer cells to grow and spread to other locations. It is important to check for stomach cancer biomarkers because new drugs can potentially target them and stop cancer growth. Learn more on our site https://lnkd.in/gtA8BFbG

MYTH All stomach cancers are the same, and every patient has the same treatment plan. FACT Stomach cancers are NOT all the same, and each patient’s type of stomach cancer has a unique set of biomarkers. – Biomarkers are bits of information unique to you and your cancer. Cancer cell biomarkers can be genes, gene mutations, or proteins that cause cancer cells to grow and spread to other locations. It is important to check for stomach cancer biomarkers because new drugs can potentially target them and stop cancer growth. Learn more - https://lnkd.in/gP_y9Fz9

Identifying proteomic risk factors for cancer ....................... ..........using prospective and exome analyses of 1463 circulating proteins and risk of 19 cancers in the UK Biobank Solid advancements: "In conclusion, we discovered multiple associations between blood proteins and cancer risk. Many of these were detectable more than seven years before cancer diagnosis and had concordant evidence from genetic analyses, suggesting they may have a role in cancer development. We also identified proteins that may mark early cancer processes among carriers of established cancer risk variants, which may serve as potential biomarkers for risk stratification and early diagnosis." https://lnkd.in/eHhHMqjW

Hey friends! Exciting news - my colleagues and I just published a study on breast cancer! We discovered a new pathway for the WASF3 gene's activity, impacting cancer progression and drug resistance. Our findings reveal a mechanism by which WASF3 overexpression affects the expression of circRNAs hsa-circ-0100153, promoting breast cancer progression by sponging hsa-miR-31/hsa-miR-767-3p /hsa-miR-935. This mechanism may increase the invasive potential of cancers, in addition to other reported molecular mechanisms involving the WASF3 gene. Understanding these mechanisms is crucial for tackling drug resistance in cancer treatment. 🧬🔬 (https://lnkd.in/eQMfukSy) TITLE: WASF3 overexpression affects the expression of circular RNA hsa-circ-0100153, which promotes breast cancer progression by sponging hsa-miR-31, hsa-miR-767-3p, and hsa-miR-935

https://lnkd.in/gmvZ8c4E CANCER BIOMARKERS – Co-Analysis of CTCs & ctDNA: Gaining Multi-Dimensional Insights Into Cancer Heterogeneity: Yoon-Tae Kang, PhD, Abiodun Bodunrin, PhD, and Joby Chesnick, PhD, MBA, believe co-analysis of CTC abundance and phenotypic changes together with ctDNA concentration could allow for real-time monitoring of disease progression and reoccurrence, while genetic and epigenetic changes in CTCs and ctDNA mutations over time could provide valuable insights into the effectiveness of therapeutic interventions, as the presence of different somatic mutations may indicate cancer susceptibility or resistance to certain treatments.

WHAT IS ALK POSTIVE LUNG CANCER? It is a type of cancer with no know cure. It occurs in only about 5% of all lung cancer patients, but occurs in approximately 30% of lung cancer patients diagnosed under age 40. It is caused by a mutation of the ALK gene, a non hereditary gene. It is estimate that 100,000 people are diagnosed with ALK Positve lung cancer each year, with 95% of diagnoses occuing at stage 4 - where it has spread (metastasized) to other organs. The lives of those with ALK Postive lung cancer depend on research.

What Causes Refractory Myeloma?#Car-T Refractory myeloma develops as a result of cancer cells making certain changes. The longer cancer cells live, grow, and divide, the more gene changes (mutations) they collect. Some of these mutations can help protect the cancer cells from being killed by medications. For example, some mutations may allow cancer cells to pump cancer drugs out, preventing the medication from doing its job. Additionally, myeloma cells cause bone marrow changes that make it easier for the cells to survive. By modifying their environment, the cells may be able to “hide” from cancer drugs and the immune system. As a result, myeloma becomes more difficult to treat.

CAR T-cell therapies: A quick overview 🔬 CAR T-cell therapies are revolutionizing cancer treatment. By genetically modifying T cells with a chimeric antigen receptor (CAR), these therapies target specific tumor antigens with high precision. Once modified, CAR T-cells are reintroduced into the patient’s bloodstream to locate, bind to, and destroy cancer cells. This approach has made it possible to cure previously incurable cancers. Currently, six CAR T-cell therapies are approved for blood cancers. While successful, these therapies face challenges like relapse rates and limited effectiveness in solid tumors. We are addressing these issues with our iTANK platform, enhancing CAR T-cell therapies for a broader range of cancers. Find out more about CAR T-cell therapies on our website: https://lnkd.in/ee-5pT4h #CARTCellTherapy #CancerTreatment #Immunotherapy

Why Men Should be Screened for the ‘Breast Cancer Gene’ https://lnkd.in/giV6h6eW New research shows that men can carry mutations in the BRCA1 and BRCA2 genes that increase their risk of several cancers, but new national guidelines are helping to educate patients. Newly developed guidelines offer hope for identifying the cancer risk of BRCA mutations in men through genetic testing and tailored cancer screening, according to an article published in JAMA Oncology. Identification of genetic risks can lead to tailored screening, finding cancers earlier and thus improve their chances for better cancer treatment outcomes. Male carriers of BRCA1/2 mutations are at higher risk of prostate, pancreatic, breast and other cancers over the course of their lifetimes. The post Why Men Should be Screened for the ‘Breast Cancer Gene’ appeared first on Life Science Washington . Click here to view original post Click Here to Publish/Feature Your Company or Product News with Biotech Networks

Oncogene: The name of oncogene suggests it is a gene that can cause cancer. Initially, oncogenes were identified in viruses, which could cause cancers in animals. Later, it was found that oncogenes can be mutated copies of certain normal cellular genes also called proto-oncogenes. Intact proto-oncogenes play important functions, regulating normal cellular growth, division, and apoptosis, which is the name for programmed or controlled cell death. Oncogenes or mutated copies of the proto-oncogenes may lead to uncontrolled cell growth and the escape from cell death, which may result in cancer development.